文献速递炎症性肠病

加用免疫调节剂可逆转接受阿达木单抗治疗患者的抗体形成与应答丧失

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-16

该研究回顾三个三级医疗中心数据库,纳入23例阿达木单抗单药治疗期间出现抗阿达木单抗抗体(AAA)并临床应答丧失(LOR)的炎症性肠病患者,加用免疫调节剂作为挽救联合治疗后,11例(48%)实现血清逆转、药物谷浓度升高和临床应答恢复,中位血清逆转时间5个月;12例(52%)未能逆转。作者结论认为近半数患者可逐渐逆转免疫原性并恢复临床-生物学应答,但需更大研究证实。

要点

  • 23例阿达木单抗单药治疗出现AAA及LOR的炎症性肠病患者加用免疫调节剂后,11例(48%)实现血清逆转并恢复临床应答。
  • 血清逆转表现为AAA逐渐消除、药物谷浓度升高及临床应答恢复,中位时间5个月。
  • 12例(52%)免疫原性和应答丧失未能逆转;应答者与非应答者在免疫调节剂类型或基线临床特征上无差异。

核心结论

  • 在出现抗阿达木单抗抗体和应答丧失的炎症性肠病患者中,近半数(11/23,48%)加用免疫调节剂治疗可逐渐逆转已形成的免疫原性并恢复临床-生物学应答。
  • 作者指出这些观察结果需更大规模研究证实。

研究设计与样本

  • 回顾三个三级医疗中心数据库,识别阿达木单抗单药治疗期间出现AAA并导致LOR、随后接受免疫调节剂作为挽救联合治疗的患者。
  • 共纳入23例患者,其中克罗恩病21例、溃疡性结肠炎2例;免疫调节剂为硫嘌呤类14例、甲氨蝶呤9例。
  • 所有血清均采用先前描述的ELISA法前瞻性分析,临床应答采用相应临床评分判定。

主要发现

  • 11例(48%)实现血清逆转,表现为AAA逐渐消除、药物谷浓度升高和临床应答恢复,中位血清逆转时间5个月。
  • 12例(52%)免疫原性和应答丧失未能逆转。
  • 应答者与非应答者在所用免疫调节剂类型或基线临床特征方面无差异。

关键数值与推荐

  • 血清逆转定义为AAA消除;同时观察药物谷浓度升高和临床应答恢复。
  • 23例中11例(48%)实现血清逆转,中位时间5个月;12例(52%)未逆转。

局限性

  • 作者指出这些观察结果需更大规模研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-adalimumab antibodies (AAA) are associated with loss of clinical response (LOR). Addition of an immunomodulator has been shown to reverse immunogenicity and regain response with infliximab monotherapy. Similar data on adalimumab are lacking. AIM: To study the impact of immunomodulator addition on the emergence of AAA and LOR among adalimumab therapy patients. METHODS: The databases of three tertiary medical centres were reviewed to identify patients who developed AAA during adalimumab monotherapy with resultant LOR, and received an immunomodulator as a salvage combination therapy. All sera were prospectively analysed using previously described ELISA assays. Clinical response was determined using appropriate clinical scores. Elimination of AAA, designated as 'sero-reversal', elevation of drug levels and regained clinical response were the sought outcomes. RESULTS: Twenty-three patients (21 Crohn's disease, and 2 ulcerative colitis) developed AAA with subsequent LOR and were thereafter prescribed an immunomodulator as salvage therapy (thiopurine n = 14, methotrexate n = 9). Eleven patients (48%) underwent sero-reversal with gradual elimination of AAA, increase in drug trough levels and restoration of clinical response (median time to sero-reversal 5 months). In 12 patients (52%), immunogenicity and loss of response could not be reversed. There was no difference between responders and nonresponders in the type of immunomodulators used or baseline clinical characteristics. CONCLUSIONS: In almost half of inflammatory bowel disease patients developing anti-adalimumab antibodies and loss of response, established immunogenicity of adalimumab can be gradually reversed by the addition of immunomodulator therapy with restoration of a clinico-biological response. However, these observations need to be confirmed with larger studies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2016. PMID: 27862102. doi:10.1111/apt.13862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。